956 results on '"Dechartres, A."'
Search Results
102. P133 - Patient and public involvement in randomised controlled trials addressing a chronic condition: methodological review
- Author
-
M. Husson, A. Dechartres, M. L'Henaff, E. Jehanno, F. Tubach, and A. Caille
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Published
- 2023
103. P112 - Utilisation du score de propension à haute dimension en pharmaco-épidémiologie : une revue systématique méthodologique
- Author
-
G. Martin, J. Rozenberg, F. Tubach, L. Létinier, and A. Dechartres
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Published
- 2023
104. Recruitment and implementation challenges were common in stepped-wedge cluster randomized trials: Results from a methodological review
- Author
-
Agnes Caille, Monica Taljaard, Floriane Le Vilain—Abraham, Alexis Le Moigne, Andrew J. Copas, Florence Tubach, Agnes Dechartres, Dechartres, Agnès, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR des Sciences Pharmaceutiques et Biologiques (Nantes Université - UFR Pharmacie), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Ottawa Hospital Research Institute [Ottawa] (OHRI), University of Ottawa [Ottawa], and University College of London [London] (UCL)
- Subjects
reporting ,Epidemiology ,[SDV]Life Sciences [q-bio] ,design ,Research Personnel ,[SDV] Life Sciences [q-bio] ,recruitment ,Research Design ,Stepped-wedge cluster randomized trial ,Humans ,Cluster Analysis ,methodological review ,implementation ,Randomized Controlled Trials as Topic - Abstract
International audience; To explore challenges in recruitment and intervention implementation in recent stepped-wedge cluster randomized trials (SW-CRTs). Study design and setting: We searched PubMed to identify primary reports of SW-CRTs (2019-2020). Two reviewers independently screened studies and extracted data from each report. Recruitment challenge was defined as planned number of clusters or participants not achieved, or any reported changes made to the design to address recruitment difficulties. Implementation challenge was defined as early, late or no implementation of the intervention in at least one cluster. Results: Of 55 SW-CRTs, 18 (33%) had a recruitment challenge, 23 (42%) had none, and for 14 (26%) it was impossible to judge. At least one implementation challenge was present in 24 (44%), 8 (15%) had none, and for 23 (42%) it was impossible to judge. Of the 35 (64%) trials with recruitment or implementation challenges, 18 (72%) had one or more modifications of their design, most often a modification of the trial duration. Conclusion: Investigators must be aware of the risks of recruitment or implementation challenges when considering use of a SW-CRT design. Mitigating strategies should be adopted when planning the trial. More transparent reporting of planned and actual design features is required.
- Published
- 2022
105. Usefulness of serum procalcitonin and point-of-care multiplex PCR gastro-intestinal panel in acute diarrhoea or colitis in the emergency department.
- Author
-
Cancella de Abreu, Marta, Cassard, Clementine, Cherubini, Ilaria, Houas, Enfel, Dechartres, Agnès, and Hausfater, Pierre
- Subjects
DIARRHEA ,HOSPITAL emergency services ,COLITIS ,CALCITONIN ,RESPIRATORY infections - Abstract
Acute infectious diarrhoea is one of the most common diseases worldwide. Procalcitonin (PCT) is useful for antibiotic stewardship in lower respiratory tract infections but has been poorly studied in infectious diarrhoea. Our objective is to describe the PCT concentrations according to diarrhoea aetiology. This is a single-center prospective cohort study involving adults consulting the emergency department (ED) for an acute diarrhoea or colitis. Serum PCT was measured and a stool sample was tested with FilmArray® Gastro-Intestinal Panel. The primary endpoint is the PCT concentration according to each type of pathogen identified using Gastro-Intestinal-panel and/or stool cultures at ED admission. 125 patients were included: 80 had an acute infectious diarrhoea, 21 an acute colitis and 24 another illness causing diarrhoea. The median (interquartile ranges) PCT values (ng/ml) were 0.13 (0.08-0.28), 0.07 (0.06-0.54), 0.13 (0.09-0.26) and 0.05 (0.03-0.17), respectively if there was a bacteria (n = 41), parasite (n = 3), virus (n = 10) or no pathogen identified and 0.34 (0.13-1.03) if the diarrhoea was due to another illness (n = 24). In patients admitted to the ED with an acute infectious diarrhoea or acute colitis, PCT remained low when a bacteria was identified. It may not be informative in current practice to guide antibiotic therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
106. Avoidable waste of research related to outcome planning and reporting in clinical trials
- Author
-
Yordanov, Youri, Dechartres, Agnes, Atal, Ignacio, Tran, Viet-Thi, Boutron, Isabelle, Crequit, Perrine, and Ravaud, Philippe
- Published
- 2018
- Full Text
- View/download PDF
107. Antineutrophil Cytoplasm Antibody-Associated Vasculitides Valvular Impairment: Multicenter Retrospective Study and Systematic Review of the Literature
- Author
-
Lina Jeantin, Tiphaine Lenfant, Pierre Bataille, Hubert de Boysson, Pascal Cathébras, Christian Agard, Stanislas Faguer, Vincent Poindron, Marc Ruivard, Nicolas Martin Silva, Matthieu Monge, Loic Guillevin, Xavier Puéchal, Benjamin Terrier, Agnès Dechartres, and Pierre Charles
- Subjects
Cytoplasm ,Rheumatology ,Endocarditis ,Immunology ,Granulomatosis with Polyangiitis ,Immunology and Allergy ,Humans ,Microscopic Polyangiitis ,Multicenter Studies as Topic ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,Retrospective Studies ,Antibodies, Antineutrophil Cytoplasmic - Abstract
ObjectiveWhile myocardial impairment is a predictor of poor prognosis in antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), little is known about valvular involvement. This study aims at describing the clinical presentation, management, and outcome of endocarditis associated with AAV.MethodsWe conducted a multicenter retrospective study in centers affiliated with the French Vasculitis Study Group. We included patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic GPA with endocardial impairment. A systematic review was then performed through PubMed, Embase, and Cochrane Library from inception up to September 2020.ResultsThe retrospective cohort included 9 patients (82%) with GPA, 1 (9%) with MPA, and 1 (9%) with unclassified AAV. Clinical presentation included acute valvular insufficiency (n = 7, 64%), cardiac failure (n = 3, 27%), dyspnea (n = 3, 27%), and no symptoms (n = 2, 18%). The aortic valve was the most frequently affected (n = 8/10, 80%), and vegetations were noted in 4 of 10 patients (40%). Six patients (55%) underwent surgical valvular replacement. No death from endocarditis was reported. The systematic review retrieved 42 patients from 40 references: 30 (71%) had GPA, 21 (50%) presented with vegetations, the aortic valve (n = 26, 62%) was the most frequently involved. Valvular replacement was required in 20 cases (48%) and 5 patients (13%) died from the endocarditic impairment.ConclusionEndocarditis is a rare and potentially life-threatening manifestation of AAV. Acute valvular insufficiency may lead to urgent surgery. Implementing transthoracic echocardiography in standard assessment at baseline and follow-up of AAV might reduce the delay to diagnosis and allow earlier immunosuppressive treatment before surgery is needed.
- Published
- 2022
108. Platelet transfusions in cancer patients with hypoproliferative thrombocytopenia in the intensive care unit
- Author
-
Habr, Bassem, Charpentier, Julien, Champigneulle, Benoît, Dechartres, Agnès, Daviaud, Fabrice, Geri, Guillaume, Cariou, Alain, Chiche, Jean-Daniel, Mira, Jean-Paul, and Pène, Frédéric
- Published
- 2015
- Full Text
- View/download PDF
109. Timing and causes of death in septic shock
- Author
-
Daviaud, Fabrice, Grimaldi, David, Dechartres, Agnès, Charpentier, Julien, Geri, Guillaume, Marin, Nathalie, Chiche, Jean-Daniel, Cariou, Alain, Mira, Jean-Paul, and Pène, Frédéric
- Published
- 2015
- Full Text
- View/download PDF
110. Meta-analyses frequently include old trials that are associated with a larger intervention effect: a meta-epidemiological study
- Author
-
Violaine Smail-Faugeron, Aidan Tan, Agnès Caille, Youri Yordanov, David Hajage, Florence Tubach, Guillaume Martin, Agnès Dechartres, Dechartres, Agnès, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), National Healthcare Group [Singapore] (NHG), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR des Sciences Pharmaceutiques et Biologiques (Nantes Université - UFR Pharmacie), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Pharmacoépidémiologie et évaluation des soins [iPLesp] (PEPITES), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
- Subjects
meta-analysis ,[SDV] Life Sciences [q-bio] ,Epidemiologic Studies ,systematic review ,Epidemiology ,[SDV]Life Sciences [q-bio] ,external validity ,Odds Ratio ,Humans ,publication date ,meta-epidemiology ,Aged - Abstract
To assess whether meta-analyses include older randomized controlled trials (RCTs) and whether intervention effect differ between older and recent RCTs.In this meta-epidemiological study of 295 meta-analyses (2940 RCTs) published in 2017-2018, we evaluated the difference in intervention effects between older (i.e., published before 2000) and recent RCTs. We also compared effects by quarters of publication year within each meta-analysis (from quarter 1 including the 25% oldest trials to quarter 4 including the 25% most recent trials). A ratio of odds ratio (ROR)1 indicates larger effects in older than recent RCTs.Trials published before 2000 and before 1990 represented 25% and 10% of all trials, respectively. Intervention effects were significantly larger for old than recent RCTs (ROR = 0.92, 95% confidence interval [CI] 0.85-1.00, IIntervention effects were larger for older than recent RCTs. Meta-analyses including older trials should be interpreted cautiously.
- Published
- 2021
111. Antineutrophil Cytoplasm Antibody–Associated Vasculitides Valvular Impairment: Multicenter Retrospective Study and Systematic Review of the Literature
- Author
-
Jeantin, Lina, primary, Lenfant, Tiphaine, additional, Bataille, Pierre, additional, de Boysson, Hubert, additional, Cathébras, Pascal, additional, Agard, Christian, additional, Faguer, Stanislas, additional, Poindron, Vincent, additional, Ruivard, Marc, additional, Silva, Nicolas Martin, additional, Monge, Matthieu, additional, Guillevin, Loic, additional, Puéchal, Xavier, additional, Terrier, Benjamin, additional, Dechartres, Agnès, additional, and Charles, Pierre, additional
- Published
- 2022
- Full Text
- View/download PDF
112. Algorithmes pour l'identification des maladies ophtalmiques dans les bases de données médico-administratives : une revue systématique de la littérature
- Author
-
Neau, J., primary, Turpin, A., additional, Tubach, F., additional, Dechartres, A., additional, and Guillo, S., additional
- Published
- 2022
- Full Text
- View/download PDF
113. Difficultés de recrutement et d'implémentation de l'intervention dans les essais randomisés en cluster en « stepped-wedge »
- Author
-
Caille, A., primary, Taljaard, M., additional, Vilain-Abraham, F. Le, additional, Moigne, A. Le, additional, Copas, A., additional, Tubach, F., additional, and Dechartres, A., additional
- Published
- 2022
- Full Text
- View/download PDF
114. Influence of trial sample size on treatment effect estimates: meta-epidemiological study
- Author
-
Dechartres, Agnes, Trinquart, Ludovic, Boutron, Isabelle, and Ravaud, Philippe
- Published
- 2013
115. Mortality of Older Patients Admitted to an ICU: A Systematic Review*
- Author
-
Bertrand Guidet, Agnès Dechartres, Dylan W. de Lange, Hans Flaatten, Gabriele Leonie Schwarz, and Helene Vallet
- Subjects
Male ,medicine.medical_specialty ,Multivariate analysis ,Critical Care ,Critical Illness ,medicine.medical_treatment ,MEDLINE ,Cochrane Library ,Critical Care and Intensive Care Medicine ,Article ,Risk Factors ,Interquartile range ,Intensive care ,Outcome Assessment, Health Care ,medicine ,Humans ,Hospital Mortality ,Critical Care Outcomes ,Aged ,Aged, 80 and over ,Mechanical ventilation ,business.industry ,Mortality rate ,Prognosis ,Europe ,Intensive Care Units ,Data extraction ,North America ,Emergency medicine ,Female ,business - Abstract
Objectives To conduct a systematic review of mortality and factors independently associated with mortality in older patients admitted to ICU. Data sources MEDLINE via PubMed, EMBASE, the Cochrane Library, and references of included studies. Study selection Two reviewers independently selected studies conducted after 2000 evaluating mortality of older patients (≥ 75 yr old) admitted to ICU. Data extraction General characteristics, mortality rate, and factors independently associated with mortality were extracted independently by two reviewers. Disagreements were solved by discussion within the study team. Data synthesis Because of expected heterogeneity, no meta-analysis was performed. We selected 129 studies (median year of publication, 2015; interquartile range, 2012-2017) including 17 based on a national registry. Most were conducted in Europe and North America. The median number of included patients was 278 (interquartile range, 124-1,068). ICU and in-hospital mortality were most frequently reported with considerable heterogeneity observed across studies that was not explained by study design or location. ICU mortality ranged from 1% to 51%, in-hospital mortality from 10% to 76%, 6-month mortality from 21% to 58%, and 1-year mortality from 33% to 72%. Factors addressed in multivariate analyses were also heterogeneous across studies. Severity score, diagnosis at admission, and use of mechanical ventilation were the independent factors most frequently associated with ICU mortality, whereas age, comorbidities, functional status, and severity score at admission were the independent factors most frequently associated with 3- 6 and 12 months mortality. Conclusions In this systematic review of older patients admitted to intensive care, we have documented substantial variation in short- and long-term mortality as well as in prognostic factors evaluated. To better understand this variation, we need consistent, high-quality data on pre-ICU conditions, ICU physiology and treatments, structure and system factors, and post-ICU trajectories. These data could inform geriatric care bundles as well as a core data set of prognostic factors to inform patient-centered decision-making.
- Published
- 2020
116. Characteristics and Management of IgA Vasculitis (Henoch‐Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey
- Author
-
Audemard‐Verger, Alexandra, Terrier, Benjamin, Dechartres, Agnès, Chanal, Johan, Amoura, Zahir, Le Gouellec, Noémie, Cacoub, Patrice, Jourde‐Chiche, Noémie, Urbanski, Geoffrey, Augusto, Jean‐François, Moulis, Guillaume, Raffray, Loic, Deroux, Alban, Hummel, Aurélie, Lioger, Bertrand, Catroux, Mélanie, Faguer, Stanislas, Goutte, Julie, Martis, Nihal, Maurier, François, Rivière, Etienne, Sanges, Sébastien, Baldolli, Aurélie, Costedoat‐Chalumeau, Nathalie, Roriz, Mélanie, Puéchal, Xavier, André, Marc, Lavigne, Christian, Bienvenu, Boris, Mekinian, Arsène, Zagdoun, Elie, Girard, Charlotte, Bérezné, Alice, Guillevin, Loïc, Thervet, Eric, and Pillebout, Evangéline
- Published
- 2017
- Full Text
- View/download PDF
117. Granulomatosis with polyangiitis according to geographic origin and ethnicity: clinical-biological presentation and outcome in a French population
- Author
-
Terrier, Benjamin, Dechartres, Agnès, Deligny, Christophe, Godmer, Pascal, Charles, Pierre, Hayem, Gilles, Dunogué, Bertrand, de Bandt, Michel, Cohen, Pascal, Puéchal, Xavier, Jeunne, Claire Le, Arfi, Serge, Mouthon, Luc, and Guillevin, Loïc
- Published
- 2017
- Full Text
- View/download PDF
118. Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study
- Author
-
Bafeta, Aïda, Dechartres, Agnes, Trinquart, Ludovic, Yavchitz, Amélie, Boutron, Isabelle, and Ravaud, Philippe
- Published
- 2012
119. Enhanced Recovery Pathway in Lung Resection Surgery: Program Establishment and Results of a Cohort Study Encompassing 1243 Consecutive Patients
- Author
-
Nguyen, Yen-Lan, primary, Maiolino, Elena, additional, De Pauw, Vincent, additional, Prieto, Mathilde, additional, Mazzella, Antonio, additional, Peretout, Jean-Baptiste, additional, Dechartres, Agnès, additional, Baillard, Christophe, additional, Bobbio, Antonio, additional, Daffré, Elisa, additional, and Alifano, Marco, additional
- Published
- 2022
- Full Text
- View/download PDF
120. Extracorporeal life support for patients with acute respiratory distress syndrome: report of a Consensus Conference
- Author
-
Richard, Christian, Argaud, Laurent, Blet, Alice, Boulain, Thierry, Contentin, Laetitia, Dechartres, Agnès, Dejode, Jean-Marc, Donetti, Laurence, Fartoukh, Muriel, Fletcher, Dominique, Kuteifan, Khaldoun, Lasocki, Sigismond, Liet, Jean-Michel, Lukaszewicz, Anne-Claire, Mal, Hervé, Maury, Eric, Osman, David, Outin, Hervé, Richard, Jean-Christophe, Schneider, Francis, and Tamion, Fabienne
- Published
- 2014
- Full Text
- View/download PDF
121. Comparison of Estimates between Cohort and Case-Control Studies in Meta-Analyses of Therapeutic Interventions: A Meta-Epidemiological Study.
- Author
-
Amy Lanza, Philippe Ravaud, Carolina Riveros, and Agnes Dechartres
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Observational studies are increasingly being used for assessing therapeutic interventions. Case-control studies are generally considered to have greater risk of bias than cohort studies, but we lack evidence of differences in effect estimates between the 2 study types. We aimed to compare estimates between cohort and case-control studies in meta-analyses of observational studies of therapeutic interventions by using a meta-epidemiological study. METHODS:We used a random sample of meta-analyses of therapeutic interventions published in 2013 that included both cohort and case-control studies assessing a binary outcome. For each meta-analysis, the ratio of estimates (RE) was calculated by comparing the estimate in case-control studies to that in cohort studies. Then, we used random-effects meta-analysis to estimate a combined RE across meta-analyses. An RE < 1 indicated that case-control studies yielded larger estimates than cohort studies. RESULTS:The final analysis included 23 meta-analyses: 138 cohort and 133 case-control studies. Treatment effect estimates did not significantly differ between case-control and cohort studies (combined RE 0.97 [95% CI 0.86-1.09]). Heterogeneity was low, with between-meta-analysis variance τ2 = 0.0049. Estimates did not differ between case-control and prospective or retrospective cohort studies (RE = 1.05 [95% CI 0.96-1.15] and RE = 0.99 [95% CI, 0.83-1.19], respectively). Sensitivity analysis of studies reporting adjusted estimates also revealed no significant difference (RE = 1.03 [95% CI 0.91-1.16]). Heterogeneity was also low for these analyses. CONCLUSION:We found no significant difference in treatment effect estimates between case-control and cohort studies assessing therapeutic interventions.
- Published
- 2016
- Full Text
- View/download PDF
122. ECMO for severe ARDS: systematic review and individual patient data meta-analysis
- Author
-
David Hajage, Alain Combes, Darryl Abrams, Diana Elbourne, Giles J. Peek, Agnès Dechartres, Matthieu Schmidt, and Pollyanna Hardy
- Subjects
Risk ,ARDS ,medicine.medical_specialty ,Randomization ,Original ,Individual patient data meta-analysis ,medicine.medical_treatment ,Critical Care and Intensive Care Medicine ,03 medical and health sciences ,Extracorporeal Membrane Oxygenation ,0302 clinical medicine ,Internal medicine ,Anesthesiology ,medicine ,Extracorporeal membrane oxygenation ,Humans ,Randomized Controlled Trials as Topic ,Respiratory Distress Syndrome ,Cross-Over Studies ,Acute respiratory distress syndrome ,business.industry ,Adult patients ,030208 emergency & critical care medicine ,Patient data ,medicine.disease ,Respiration, Artificial ,Confidence interval ,3. Good health ,surgical procedures, operative ,030228 respiratory system ,Meta-analysis ,Relative risk ,business - Abstract
Purpose To assess the effect of venovenous extracorporeal membrane oxygenation (ECMO) compared to conventional management in patients with severe acute respiratory distress syndrome (ARDS). Methods We conducted a systematic review and individual patient data meta-analysis of randomised controlled trials (RCTs) performed after Jan 1, 2000 comparing ECMO to conventional management in patients with severe ARDS. The primary outcome was 90-day mortality. Primary analysis was by intent-to-treat. Results We identified two RCTs (CESAR and EOLIA) and combined data from 429 patients. On day 90, 77 of the 214 (36%) ECMO-group and 103 of the 215 (48%) control group patients had died (relative risk (RR), 0.75, 95% confidence interval (CI) 0.6–0.94; P = 0.013; I2 = 0%). In the per-protocol and as-treated analyses the RRs were 0.75 (95% CI 0.6–0.94) and 0.86 (95% CI 0.68–1.09), respectively. Rescue ECMO was used for 36 (17%) of the 215 control patients (35 in EOLIA and 1 in CESAR). The RR of 90-day treatment failure, defined as death for the ECMO-group and death or crossover to ECMO for the control group was 0.65 (95% CI 0.52–0.8; I2 = 0%). Patients randomised to ECMO had more days alive out of the ICU and without respiratory, cardiovascular, renal and neurological failure. The only significant treatment-covariate interaction in subgroups was lower mortality with ECMO in patients with two or less organs failing at randomization. Conclusions In this meta-analysis of individual patient data in severe ARDS, 90-day mortality was significantly lowered by ECMO compared with conventional management. Electronic supplementary material The online version of this article (10.1007/s00134-020-06248-3) contains supplementary material, which is available to authorized users.
- Published
- 2020
123. Cardiac Intravoxel Incoherent Motion Diffusion‐Weighted Magnetic Resonance Imaging With T1 Mapping to Assess Myocardial Perfusion and Fibrosis in Systemic Sclerosis: Association With Cardiac Events From a Prospective Cohort Study
- Author
-
Alice Bérezné, Claire Le Jeunne, Moncef Ben Arfi, Agnès Dechartres, Bertrand Dunogué, Loïc Guillevin, Alexis Régent, Jonathan London, Benjamin Terrier, Hervé Gouya, Luc Mouthon, Paul Legmann, Pascal Cohen, and Olivier Vignaux
- Subjects
Adult ,Male ,medicine.medical_specialty ,Vital capacity ,Heart Diseases ,Immunology ,Myocardial Infarction ,Cohort Studies ,Myocardial perfusion imaging ,Rheumatology ,Scleroderma, Limited ,Cardiac magnetic resonance imaging ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Lung volumes ,Angina, Unstable ,Prospective Studies ,Progression-free survival ,Prospective cohort study ,Intravoxel incoherent motion ,Aged ,Heart Failure ,Scleroderma, Systemic ,medicine.diagnostic_test ,business.industry ,Myocardium ,Myocardial Perfusion Imaging ,Interstitial lung disease ,Arrhythmias, Cardiac ,Middle Aged ,medicine.disease ,Fibrosis ,Magnetic Resonance Imaging ,Progression-Free Survival ,Hospitalization ,Diffusion Magnetic Resonance Imaging ,Case-Control Studies ,Scleroderma, Diffuse ,Cardiology ,Female ,Cardiomyopathies ,business - Abstract
Objective Myocardial involvement may occur during systemic sclerosis (SSc) and can lead to impaired myocardial contraction and/or arrhythmia. Cardiac magnetic resonance imaging (MRI) is used for noninvasive characterization of the myocardium. The aim of this study was to evaluate the utility of cardiac MRI with intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) and longitudinal relaxation time (T1) sequence mapping for assessment of myocardial microvascular and interstitium impairment in SSc. Methods In this single-center prospective cohort study, 40 consecutive patients with SSc and 20 healthy controls were assessed by cardiac MRI with IVIM DWI and T1 mapping sequences on a 3T scanning system. Images were analyzed independently by 2 assessors, and Bland-Altman plots were used to assess interreader concordance and reproducibility. Characteristics of the patients were compared according to quartiles of T1 and perfusion fraction (f-coefficient) values, using exact Cochran-Ermitage trend tests for qualitative variables and analysis of variance for quantitative variables. Kaplan-Meier cardiac events-free survival curves were plotted and compared with a log-rank test for trend. Results T1 values were higher in SSc patients than in healthy controls, and were higher in the diffuse cutaneous SSc (dcSSc) subset (P = 0.02). Higher T1 values were associated with the immunologic pattern seen in patients with the dcSSc form (P = 0.0001), a higher modified Rodnan skin thickness score (MRSS) (P = 0.003), and a higher frequency of interstitial lung disease (P = 0.03). Moreover, higher T1 values were correlated with higher MRSS scores (r = +0.32, P = 0.04) and reduced forced vital capacity (r = -0.34, P = 0.048), and tended to be correlated with reduced total lung capacity (r = -0.30, P = 0.07). Lower f-coefficient values, as a measure of decreased tissue perfusion, were associated with less frequent use of vasodilators (P = 0.02 for angiotensin-converting enzyme inhibitors and P = 0.06 for calcium-channel blockers) and more frequent use of glucocorticoids (P = 0.02). The f-coefficients were inversely correlated with the T1 values (r = -0.31, P = 0.02). Furthermore, higher T1 values were associated with higher incidence of cardiac events (log-rank test for trend P = 0.03). Conclusion Increased T1 values, potentially suggesting microscopic fibrosis, were observed more frequently in patients with dcSSc, and higher T1 values were associated with interstitial lung disease and more frequent cardiac events during follow-up. The results of this study show that cardiac MRI with T1 mapping sequences and IVIM DWI may be useful in assessing myocardial involvement in patients with SSc.
- Published
- 2020
124. Simulation in psychiatry for medical doctors: A systematic review and meta-analysis
- Author
-
Gilles Guerrier, Carine Layat Burn, Bruno Falissard, Jan-Joost Rethans, Grégoire Billon, Daphné Michelet, Chris Attoe, Marie-Aude Piot, Sean Cross, Antoine Tesniere, Cédric Lemogne, Fabrice Jollant, and Agnès Dechartres
- Subjects
medicine.medical_specialty ,Students, Medical ,communication-skills ,020205 medical informatics ,undergraduate psychiatry ,Psychological intervention ,MEDLINE ,Context (language use) ,02 engineering and technology ,Simulated patient ,Education ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,0202 electrical engineering, electronic engineering, information engineering ,medicine ,Humans ,Computer Simulation ,030212 general & internal medicine ,Psychiatry ,STANDARDIZED PATIENTS ,business.industry ,Mental Disorders ,primary-care ,health nursing-education ,General Medicine ,RANDOMIZED CONTROLLED-TRIAL ,Mental health ,Confidence interval ,mental-health ,Meta-analysis ,residents ,Educational Status ,training health ,business ,INTERVENTION - Abstract
Context Most medical doctors are likely to work with patients experiencing mental health conditions. However, educational opportunities for medical doctors to achieve professional development in the field of psychiatry are often limited. Simulation training in psychiatry may be a useful tool to foster this development. Objectives The purpose of this study was to assess the effectiveness of simulation training in psychiatry for medical students, postgraduate trainees and medical doctors. Methods For this systematic review and meta-analysis, we searched eight electronic databases and trial registries up to 31 August 2018. We manually searched key journals and the reference lists of selected studies. We included randomised and non-randomised controlled studies and single group pre- and post-test studies. Our main outcomes were based on Kirkpatrick levels. We included data only from randomised controlled trials (RCTs) using random-effects models. Results From 46 571 studies identified, we selected 163 studies and combined 27 RCTs. Interventions included simulation by role-play (n = 69), simulated patients (n = 72), virtual reality (n = 22), manikin (n = 5) and voice simulation (n = 2). Meta-analysis found significant differences at immediate post-tests for simulation compared with active and inactive control groups for attitudes (standardised mean difference [SMD] = 0.52, 95% confidence interval [CI] 0.31-0.73 [I2 = 0.0%] and SMD = 0.28, 95% CI 0.04-0.53 [I2 = 52.0%], respectively), skills (SMD = 1.37, 95% CI 0.56-2.18 [I2 = 93.0%] and SMD = 1.49, 95% CI 0.39-2.58 [I2 = 93.0%], respectively), knowledge (SMD = 1.22, 95% CI 0.57-1.88 [I2 = 0.0%] and SMD = 0.72, 95% CI 0.14-1.30 [I2 = 80.0%], respectively), and behaviours (SMD = 1.07, 95% CI 0.49-1.65 [I2 = 68.0%] and SMD = 0.45, 95% CI 0.11-0.79 [I2 = 41.0%], respectively). Significant differences in terms of patient benefit and doctors' behaviours and skills were found at the 3-month follow-up. Conclusions Despite heterogeneity in methods and simulation interventions, our findings demonstrate the effectiveness of simulation training in psychiatry training.
- Published
- 2020
125. Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis
- Author
-
Olivier Aumaître, Xavier Puéchal, Grégory Pugnet, Pascal Godmer, François Maurier, P. Gobert, Stanislas Faguer, Mohamed Hamidou, François Lifermann, Sophie Rivière, Luc Mouthon, Noémie Jourde-Chiche, Bernard Bonnotte, Benjamin Terrier, Christian Agard, Nadine Meaux-Ruault, Loïc Guillevin, Agnès Dechartres, Antoine Huart, Nicolas Martin-Silva, Jean Sibilia, Alexandre Karras, Pierre Charles, Maxime Samson, Marie Matignon, Pascal Cohen, Jean-François Viallard, and Catherine Hanrotel-Saliou
- Subjects
medicine.medical_specialty ,Randomization ,Antigens, CD19 ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,Gastroenterology ,Disease-Free Survival ,Drug Administration Schedule ,Antibodies, Antineutrophil Cytoplasmic ,Maintenance Chemotherapy ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Maintenance therapy ,Randomized controlled trial ,law ,Internal medicine ,Post-hoc analysis ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Survival rate ,030203 arthritis & rheumatology ,business.industry ,medicine.disease ,Antirheumatic Agents ,Rituximab ,Microscopic polyangiitis ,Granulomatosis with polyangiitis ,business ,medicine.drug - Abstract
ObjectiveThe randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter’s titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12.MethodsMAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free survival rates in each arm as primary end points. Exploratory subgroup analyses were run according to CYC or rituximab induction and newly diagnosed or relapsing AAV.ResultsAt M3, M6, M9 and M12, respectively, among the 161 patients included, 79/80 (98.8%), 76/80 (95%), 74/80 (92.5%) and 73/80 (91.3%) from D0, and 80/81 (98.8%), 78/81 (96.3%), 76/81 (93.8%) and 76/81 (93.8%) from D0+D14 groups were alive and relapse-free. No between-group differences were observed. Results were not affected by CYC or rituximab induction, or newly diagnosed or relapsing AAV.ConclusionsWe were not able to detect a difference between the relapse-free survival rates for up to M12 for the D0 and D0+D14 rituximab-infusion groups, which could suggest that omitting the D14 rituximab remission-maintenance dose did not modify the short-term relapse-free rate. Nevertheless, results at M12 may also have been influenced by the rituximab-infusion strategies for both groups.
- Published
- 2020
126. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
- Author
-
Yann De Rycke, Lisa Belin, Agnès Dechartres, Aidan Tan, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Département de Biostatistique, Santé Publique et Information Médicale [CHU Pitié-Salpêtrière] (BIOSPIM ), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), National University Hospital [Singapore] (NUH), Centre de Pharmacoépidémiologie de l'AP-HP (Cephepi), and Gestionnaire, Hal Sorbonne Université
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,MEDLINE ,Cochrane Library ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Neoplasms ,medicine ,Overall survival ,Humans ,030212 general & internal medicine ,Progression-free survival ,Drug Approval ,Cancer ,Surrogate endpoint ,business.industry ,Progression-Free Survival ,[SDV] Life Sciences [q-bio] ,Outcomes research ,030220 oncology & carcinogenesis ,business ,Biomarkers - Abstract
BackgroundProgression-free survival (PFS) is a surrogate endpoint widely used for overall survival (OS) in oncology. Validation of PFS as a surrogate must be done for each indication and each intervention. We aimed to identify all studies evaluating the validity of PFS as a surrogate for OS in oncology, and to describe their methodological characteristics.MethodsWe conducted a systematic review by searching MEDLINE via PubMed and the Cochrane Library with no limitation on time, selected relevant studies and extracted data in duplicate on how surrogacy was evaluated (meta-analytic approach, assessment of correlation and level of evaluation).ResultsWe identified 91 studies evaluating the validity of PFS as a surrogate for OS in 24 cancer localisations. Although a meta-analytic approach was used in 83 (91%) studies, the methods used to validate PFS as a surrogate of OS were heterogeneous across studies. Of the 47 studies concluding that PFS is a good surrogate for OS, for 15 (32%), there was no quantitative argument for surrogacy.ConclusionsAlthough most studies used a meta-analytic approach as recommended, our methodological review highlights heterogeneity in methods and reporting, which stresses the importance of developing and applying clear recommendations in this area.
- Published
- 2020
127. Meta-analyses frequently pooled different study types together: a meta-epidemiological study
- Author
-
S Guillo, Jordan Scheer, Florence Tubach, René-Sosata Bun, Agnès Dechartres, Sorbonne Université (SU), Département de Biostatistique, Santé Publique et Information Médicale [CHU Pitié-Salpêtrière] (BIOSPIM ), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
medicine.medical_specialty ,Epidemiology ,Comparative effectiveness research ,MEDLINE ,Subgroup analysis ,law.invention ,Therapeutic intervention ,03 medical and health sciences ,0302 clinical medicine ,Meta-Analysis as Topic ,Randomized controlled trial ,law ,Internal medicine ,Humans ,Medicine ,030212 general & internal medicine ,Observational studies ,Randomized Controlled Trials as Topic ,Meta-epidemiology ,business.industry ,Confidence interval ,3. Good health ,Epidemiologic Studies ,Observational Studies as Topic ,Meta-analysis ,Systematic review ,Randomized controlled trials ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Observational study ,Epidemiologic Methods ,business ,030217 neurology & neurosurgery - Abstract
International audience; Objective: To evaluate the characteristics of therapeutic meta-analyses including both observational studies and randomized controlled trials (RCTs), how these studies were combined and whether there were differences in treatment effects.Study design and setting: Meta-epidemiological study of meta-analyses, including both observational studies and RCTs. We searched MEDLINE for the five leading journals of each medical category according to Journal Citation Reports) and Cochrane Database of Systematic Reviews, from 2014 to 2018 for eligible meta-analyses and extracted how observational studies and RCTs were combined and results for each study.Results: Of the 102 included meta-analyses, observational studies and RCTs were combined together without a subgroup analysis in 39 (38%) and with subgroup analysis in 15 (15%); they were pooled separately for the same outcome in 11 (11%) and not for the same outcome in 9 (9%). In 28 (27%) meta-analyses, only RCTs were combined, with a qualitative description of observational studies. Treatment effect estimates did not differ between observational studies and RCTs (ratio of estimates = 0.98 [95% confidence interval 0.80-1.21]), with substantial heterogeneity (I2 = 59%).Conclusion: Many meta-analyses, including both observational studies and RCTs pool results from both study types. Although treatment effects did not differ between them on average, we identified situations for which estimates differed.
- Published
- 2020
128. Migration and severe maternal outcomes in high income countries: a systematic review and meta-analysis
- Author
-
Maxime ESLIER, Elie Azria, Konstantinos Chatzistergiou, Zelda Stewart, Dechartres Agnès, and Catherine Deneux-Tharaux
- Subjects
Obstetrics and Gynecology - Published
- 2023
129. Low dose of morphine to relieve dyspnea in acute respiratory failure (OpiDys): protocol for a double-blind randomized controlled study
- Author
-
Alexandre Demoule, Robin Deleris, Côme Bureau, Said Lebbah, Maxens Decavèle, Martin Dres, Thomas Similowski, and Agnes Dechartres
- Subjects
Oxygen ,Respiratory Distress Syndrome ,Dyspnea ,Treatment Outcome ,Morphine ,SARS-CoV-2 ,Medicine (miscellaneous) ,COVID-19 ,Humans ,Pharmacology (medical) ,Saline Solution ,Respiratory Insufficiency ,Randomized Controlled Trials as Topic - Abstract
Background Dyspnea is common and severe in intensive care unit (ICU) patients managed for acute respiratory failure. Dyspnea appears to be associated with impaired prognosis and neuropsychological sequels. Pain and dyspnea share many similarities and previous studies have shown the benefit of morphine on dyspnea in patients with end-stage onco-hematological disease and severe heart or respiratory disease. In these populations, morphine administration was safe. Here, we hypothesize that low-dose opioids may help to reduce dyspnea in patients admitted to the ICU for acute respiratory failure. The primary objective of the trial is to determine whether the administration of low-dose titrated opioids, compared to placebo, in patients admitted to the ICU for acute respiratory failure with severe dyspnea decreases the mean 24-h intensity of dyspnea score. Methods In this single-center double-blind randomized controlled trial with 2 parallel arms, we plan to include 22 patients (aged 18–75 years) on spontaneous ventilation with either non-invasive ventilation, high flow oxygen therapy or standard oxygen therapy admitted to the ICU for acute respiratory failure with severe dyspnea. They will be assigned after randomization with a 1:1 allocation ratio to receive in experimental arm administration of low-dose titrated morphine hydrochloride for 24 h consisting in an intravenous titration relayed subcutaneously according to a predefined protocol, or a placebo (0.9% NaCl) administered according to the same protocol in the control arm. The primary endpoint is the mean 24-h dyspnea score assessed by a visual analog scale of dyspnea. Discussion To our knowledge, this study is the first to evaluate the benefit of opioids on dyspnea in ICU patients admitted for acute respiratory failure. Trial registration ClinicalTrials.govNCT04358133. Registered on 24 April 2020.
- Published
- 2021
130. Reporting of sample size calculation in randomised controlled trials: review
- Author
-
Charles, Pierre, Giraudeau, Bruno, Dechartres, Agnes, Baron, Gabriel, and Ravaud, Philippe
- Published
- 2009
131. Quality of Evidence in Ophthalmology: An Overview of Cochrane Reviews
- Author
-
Mikael Guedj, José-Alain Sahel, Bahram Bodaghi, Florence Tubach, Flore Salviat, and Agnès Dechartres
- Subjects
Quality of evidence ,Ophthalmology ,medicine.medical_specialty ,business.industry ,Family medicine ,MEDLINE ,Medicine ,business - Published
- 2021
132. Prognosis of Rash and Chilblain-like Lesions among Outpatients with COVID-19: A Large Cohort Study
- Author
-
Hélène, Mascitti, Patrick, Jourdain, Alexandre, Bleibtreu, Luc, Jaulmes, Agnès, Dechartres, Xavier, Lescure, Youri, Yordanov, Aurélien, Dinh, Pascaline, Villie, Hôpital Raymond Poincaré [AP-HP], Université Paris-Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7), Centre de Pharmacoépidémiologie de l'AP-HP (Cephepi), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Université Sorbonne Paris Cité (USPC), AP-HP/Universities/INSERM COVID-19 research collaboration: Caroline Apra, Arthur Mensch, Amélie Aime-Eusebi, Erwan Debuc, Agnes Dechartres, Laurène Deconinck, Christine Katlama, Josselin Lebel, François-Xavier Lescure, Yves Artigou, Amélie Banzet, Elodie Boucheron, Christiane Boudier, Edouard Buzenac, Marie-Claire Chapron, Dalhia Chekaoui, Laurent De Bastard, Alexandre Grenier, Pierre-Etienne Haas, Julien Hody, Michèle Jarraya, Louis Lacaille, Aurélie Le Guern, Jeremy Leclert, Fanny Male, Jerôme Marchand-Arvier, Emmanuel Martin-Blondet, Apolinne Nassour, Oussama Ourahou, Thomas Penn, Ambre Ribardiere, Nicolas Robin, Camille Rouge, Nicolas Schmidt, Pascaline Villie, and HAL UPMC, Gestionnaire
- Subjects
Adult ,Male ,Microbiology (medical) ,myalgia ,medicine.medical_specialty ,COVID19 ,Chilblain-like lesion ,[SDV]Life Sciences [q-bio] ,Population ,Anosmia ,Chest pain ,Cohort Studies ,Rash ,Outpatients ,Humans ,Medicine ,education ,Aged ,education.field_of_study ,SARS-CoV-2 ,business.industry ,Brief Report ,digestive, oral, and skin physiology ,COVID-19 ,General Medicine ,Exanthema ,Middle Aged ,Ageusia ,Prognosis ,Dermatology ,Chilblains ,Hospitalization ,[SDV] Life Sciences [q-bio] ,Infectious Diseases ,Risk factors ,Vomiting ,Female ,medicine.symptom ,business ,Cohort study - Abstract
In a large regional observational cohort study of adult (≥ 18 years), outpatients with COVID-19, prevalence, characteristics, and outcome of patients with rash and/or chilblain-like lesions (CLL), compared with population without cutaneous features, were studied. In total, 28,957 outpatients were included; the prevalence of rash and CCL were 9.5% and 3.7%, respectively. Presence of rash was significantly associated with presence of asthenia, shivers or myalgia, respiratory and gastro-intestinal symptoms, and anosmia/ageusia. The presence of CCL was associated with chest pain, chest oppression, nausea/vomiting, and anosmia/ageusia. Patients with CCL were significantly less prone to an unfavourable outcome (hospitalization or death). Supplementary Information The online version contains supplementary material available at 10.1007/s10096-021-04305-3.
- Published
- 2021
133. Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases
- Author
-
Dechartres, A., Chevret, S., Lambert, J., Calvo, F., and Lévy, V.
- Published
- 2011
- Full Text
- View/download PDF
134. Reviews assessing the quality or the reporting of randomized controlled trials are increasing over time but raised questions about how quality is assessed
- Author
-
Dechartres, Agnes, Charles, Pierre, Hopewell, Sally, Ravaud, Philippe, and Altman, Douglas G.
- Published
- 2011
- Full Text
- View/download PDF
135. Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials
- Author
-
Agnès Dechartres, Joe-Elie Salem, Stéphane Ederhy, Service de pharmacologie médicale [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Groupe de REcherche en Cardio Oncologie [CHU Saint-Antoine] (GRC 27 GRECO), CHU Saint-Antoine [AP-HP], Service de Cardiologie [CHU Saint-Antoine], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Service de Département de santé publique
- Subjects
Cancer Research ,Cardiotoxicity ,business.industry ,Immune checkpoint inhibitors ,MEDLINE ,Bioinformatics ,3. Good health ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,Oncology ,030220 oncology & carcinogenesis ,Meta-analysis ,Medicine ,030212 general & internal medicine ,business ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience
- Published
- 2021
136. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections
- Author
-
Grimaldi, David, Le Bourhis, Lionel, Sauneuf, Bertrand, Dechartres, Agnès, Rousseau, Christophe, Ouaaz, Fatah, and Milder, Maud
- Subjects
Medical research -- Analysis -- Health aspects ,Medicine, Experimental -- Analysis -- Health aspects ,T cells -- Analysis -- Health aspects ,Bacteria -- Analysis -- Health aspects ,Bacterial infections -- Health aspects -- Analysis ,Infection -- Health aspects -- Analysis ,Septic shock -- Analysis -- Health aspects ,Virus diseases -- Health aspects -- Analysis ,Health care industry - Abstract
Purpose In between innate and adaptive immunity, the recently identified innate-like mucosal-associated invariant T (MAIT) lymphocytes display specific reactivity to non-streptococcal bacteria. Whether they are involved in bacterial sepsis has not been investigated. We aimed to assess the number and the time course of circulating innate-like T lymphocytes (MAIT, NKT and [gamma][delta] T cells) in critically ill septic and non-septic patients and to establish correlations with the further development of intensive care unit (ICU)-acquired infections. Methods We prospectively enrolled consecutive patients with severe sepsis and septic shock. Controls were critically ill patients with non-septic shock and age-matched healthy subjects. Circulating innate-like lymphocytes were enumerated using a flow cytometry assay at day 1, 4 and 7. Results One hundred and fifty six patients (113 severe bacterial infections, 36 non-infected patients and 7 patients with severe viral infections) and 26 healthy subjects were enrolled into the study. Patients with severe bacterial infections displayed an early decrease in MAIT cell count [median 1.3/mm.sup.3; interquartile range (0.4-3.2)] as compared to control healthy subjects [31.1/mm.sup.3 (12.1-45.2)], but also to non-infected critically ill patients [4.3/mm.sup.3 (1.4-13.2)] (P < 0.0001 for all comparisons). In contrast NKT and [gamma][delta] T cell counts did not differ between patients groups. The multivariate analysis identified non-streptococcal bacterial infection as an independent determinant of decrease in MAIT cell count. Furthermore, the incidence of ICU-acquired infections was higher in patients with persistent MAIT cell depletion. Conclusions This large human study provides valuable information about MAIT cells in severe bacterial infections. The persistent depletion of MAIT cells is associated with the further development of ICU-acquired infections., Author(s): David Grimaldi [sup.1] [sup.2] [sup.3] [sup.4] [sup.5], Lionel Le Bourhis [sup.6] [sup.7] [sup.8], Bertrand Sauneuf [sup.1], Agnès Dechartres [sup.4] [sup.9], Christophe Rousseau [sup.2] [sup.3] [sup.4], Fatah Ouaaz [sup.2] [sup.3] [...]
- Published
- 2014
- Full Text
- View/download PDF
137. Characteristics and Public Availability of Results of Clinical Trials on Rare Diseases Registered at Clinicaltrials.gov
- Author
-
Dechartres, Agnes, Riveros, Carolina, Harroch, Michael, Faber, Timor, and Ravaud, Philippe
- Published
- 2016
- Full Text
- View/download PDF
138. Long‐term device survival after a first implantation of AMS800™ for stress urinary incontinence: Comparison between men and women.
- Author
-
Cotte, Juliette, Dechartres, Agnès, Mozer, Pierre, Poinard, Florence, Chartier‐Kastler, Emmanuel, and Beaugerie, Aurélien
- Subjects
URINARY stress incontinence ,ARTIFICIAL sphincters ,URINARY incontinence - Abstract
Purpose: The artificial urinary sphincter is the reference treatment for stress urinary incontinence in men, but it remains rarely used in women. This study aimed to compare long‐term device survival between women and men, after the first implantation of an AMS800™ artificial urinary sphincter (Boston Scientific) for the treatment of a non‐neurogenic stress urinary incontinence. Materials and Methods: This retrospective cohort study included all patients with nonneurogenic stress urinary incontinence who underwent surgery in a large‐volume university hospital between 2000 and 2013. The primary outcome was the overall survival of the device, defined as the absence of any repeated surgery (revision or explantation) during follow‐up. Men and women were matched 3:1 according to age and year of implantation. Differences were analyzed using a Cox model accounting for matching and applying time intervals because hazards were not proportional over time. Sensitivity analyzes were performed, excluding firstly a population with a history of radiotherapy and secondly a population with more than one previous surgery for urinary incontinence. Results: A total of 107 women were matched to 316 men. Median follow‐up was 6.0 years (Q1–Q3 1.8–9.4): 7.0 years (Q1–Q3 3.1–10.3) for women and 5.1 years (Q1–Q3 1.3–9.1) for men. During the follow‐up, 56 patients had an explantation of the device: 44 men (13.9%) and 12 women (11.2%), and 113 had a revision: 85 men (26.9%) and 28 women (26.1%). Men have a significantly higher risk of explantation or revision than women between 6 months and 8 years after implantation (hazard ratio 2.12 [1.29–3.48]). Before 6 months and after 8 years, there were no significant differences. Both sensitivity analyses found consistent results. Conclusions: This study suggests that device survival seems better in women after the first 6 months. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
139. Association entre taux d’androgènes et phénotypes chez 379 patientes en insuffisance ovarienne prématurée
- Author
-
C. Voisin, A. Dechartres, I. Tejedor, J. Dulon, M. Leban, A. Bachelot, and Z. Chakhtoura
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Published
- 2022
140. Assistance extracorporelle au cours du syndrome de détresse respiratoire aiguë (chez l’adulte et l’enfant, à l’exclusion du nouveau-né). Conférence de consensus organisée par la Société de réanimation de langue française
- Author
-
Richard, C., Argaud, L., Blet, A., Boulain, T., Contentin, L., Dechartres, A., Dejode, J. -M., Donetti, L., Fartoukh, M., Fletcher, D., Kuteifan, K., Lasocki, S., Liet, J. -M., Lukaszewicz, A. -C., Mal, H., Maury, E., Osman, D., Outin, H., Richard, J. -C., Schneider, F., and Tamion, F.
- Published
- 2013
- Full Text
- View/download PDF
141. Chimeric antigen receptor T ‐cells safety: A pharmacovigilance and meta‐analysis study
- Author
-
Dolladille, Charles, Ederhy, Stéphane, Ezine, Emilien, Choquet, Sylvain, Nguyen, Lee, Alexandre, Joachim, Moslehi, Javid, Dechartres, Agnès, Salem, Joe-Elie, Picard, Diane, Leroy, Rebecca, Poussy, Tifany, Tankere, Frederic, Gatignol, Peggy, Université de Caen Normandie - UFR Santé (UNICAEN Santé), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Service de Cardiologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Groupe de REcherche en Cardio Oncologie [CHU Saint-Antoine] (GRC 27 GRECO), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CMC Ambroise Paré [Neuilly-sur-Seine, France], Département de Pharmacologie [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Pharmacoépidémiologie de l'AP-HP (Cephepi), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Physiologie et physiopathologie de la motricité chez l'homme, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Gestionnaire, Hal Sorbonne Université
- Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology ,medicine.medical_specialty ,Drug-Related Side Effects and Adverse Reactions ,MESH: Bayes Theorem ,MESH: Pharmacovigilance ,Antigens, CD19 ,Receptors, Antigen, T-Cell ,Immunotherapy, Adoptive ,MESH: Nervous System Diseases ,Pharmacovigilance ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,MESH: Incidence ,MESH: Receptors, Chimeric Antigen ,Biological Products ,Receptors, Chimeric Antigen ,Lung ,MESH: Humans ,MESH: Antigens, CD19 ,business.industry ,Incidence ,Incidence (epidemiology) ,Bayes Theorem ,MESH: Receptors, Antigen, T-Cell ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,medicine.disease ,MESH: Hematologic Diseases ,Hematologic Diseases ,MESH: Drug-Related Side Effects and Adverse Reactions ,3. Good health ,Cytokine release syndrome ,medicine.anatomical_structure ,Respiratory failure ,030220 oncology & carcinogenesis ,Meta-analysis ,MESH: Cytokine Release Syndrome ,MESH: Immunotherapy, Adoptive ,Observational study ,Nervous System Diseases ,Cytokine Release Syndrome ,business ,030215 immunology ,Cohort study - Abstract
International audience; Chimeric-antigen-receptor T cells directed against CD19 (CAR-T) are emerging hematological therapeutics with scarce data on its overall safety profile spectrum. To determine the clinical features and incidence of adverse-drug reactions (ADR) associated with CAR-T. This observational, cross-sectional, pharmacovigilance cohort study examined individual case safety reports from the World Health Organization database VigiBase and meta-analysis of data from CAR-T trials and cohorts in the literature was also performed through March, 2020. The primary objective was to identify ADR associated with approved CAR-T (axicabtagene-ciloleucel; tisagenlecleucel). We conducted a Bayesian disproportionate analysis with the 95% lower credibility-interval of information component (IC025 , significance > 0). We also performed a systematic-review and meta-analysis of CAR-T trials and cohorts in the literature to evaluate ADR incidence. Nine ADR classes were associated with CAR-T: Cytokine release syndrome (CRS, n = 1378, IC025 = 4.24), neurological disorders (n = 963, IC025 = 2.42), hematological disorders (n = 532, IC025 = 3.32), infections (n = 287, IC025 = 2.38), cardiovascular disorders (n = 256, IC025 = 2.81), pulmonary disorders (n = 186, IC025 = 3.80), reno-metabolic disorders (n = 123, IC025 = 1.89), hemophagocytic-lymphohistiocytosis (n = 36, IC025 = 5.01) and hepatic disorders (n = 32, IC025 = 2.49). ADR-related fatalities accounted for 99/1783 (5.5%) of the reports and 262/1783 (14.7%) for all-cause mortality. These ADR-related fatalities were associated with hemophagocytic-lymphohistiocytosis, cerebral vascular disorder, infections, and respiratory failure. In meta-analyses, the most frequent any-grade ADRs were CRS, hematological disorders, and neurological disorders. Fatal ADR were most found with neurological disorders, CRS, and infections. Note, CAR-T infusion may be associated with severe ADR mainly following the week of administration, though rarely fatal. Infections, hemophagocytic-lymphohistiocytosis and end organ failures including neurological or lung involvements require scrutiny.
- Published
- 2021
142. Effectiveness of simulation in psychiatry for nursing students, nurses and nurse practitioners: A systematic review and meta-analysis
- Author
-
Daphné Michelet, Sean Cross, Marie-Aude Piot, Antoine Tesniere, Cédric Lemogne, Chris Attoe, Gilles Guerrier, Agnès Dechartres, Grégoire Billon, Bruno Falissard, Jan-Joost Rethans, Carine Layat Burn, Marie Romeo, and Fabrice Jollant
- Subjects
medicine.medical_specialty ,VIRTUAL PATIENTS ,education ,Psychological intervention ,COMMUNICATION ,Disease ,Manikins ,nurses ,Simulated patient ,law.invention ,nursing ,systematic review ,Randomized controlled trial ,Nursing ,law ,FRONT-LINE HEALTH ,medicine ,Humans ,Computer Simulation ,Nurse Practitioners ,Nurse education ,Psychiatry ,General Nursing ,students ,STANDARDIZED PATIENTS ,Professional development ,PRIMARY-CARE ,EDUCATION ,simulation ,Mental health ,meta-analysis ,TRAINING-PROGRAM ,FAMILY WORK ,nurse education ,Meta-analysis ,SKILLS ,Students, Nursing ,Psychology ,MENTAL-HEALTH ,mental health - Abstract
Aims Mental disorders constitute one of the main causes of disease and disability worldwide. While nurses are often at the frontline of mental health care, they have limited access to dedicated psychiatric training opportunities. Simulation training may foster the development of the appropriate competencies required when supporting people with mental disorders. To evaluate the effectiveness of simulation training in psychiatry for nursing students, nurses and nurse practitioners. Design Systematic review and meta-analysis. Data sources Eight electronic databases, trial registries, key journals and reference lists of selected studies were searched from inception to August 20, 2020 without language restriction. Review methods We included randomized and non-randomized controlled studies and single group pre/post studies. Cochrane Risk of Bias tool 2.0 was used for randomized controlled study appraisal, and the Medical Education Research Study Quality instrument was completed for all other studies. Meta-analysis was restricted to randomized controlled studies. The other studies were synthesized narratively. The main outcomes were based on Kirkpatrick levels. Results A total of 118 studies (6738 participants) were found. Interventions included simulated patients (n = 55), role-plays (n = 40), virtual reality (n = 12), manikins (n = 9) and voice simulations (n = 9). Meta-analyses based on 11 randomized controlled studies found a significant large effect size on skills at immediate post-test for simulation compared with active control; and a small and medium effect size on learners' attitudes for simulation compared with inactive control, at immediate post-test and at three-month follow-up respectively. Three quarters of non-randomized controlled studies and pre/post-tests assessing attitudes and skills showed significant differences, and three quarters of participants in randomized controlled studies and pre/post-tests showed significant differences in behaviours. Among the few studies assessing people with mental health outcomes, almost all reported significant differences. Conclusion These findings support the effectiveness of simulation training in psychiatric nursing throughout professional development grades, despite heterogeneity in methods and simulation interventions.
- Published
- 2021
143. Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
- Author
-
E. Malaurie, Claire Bosacki, Aude-Marie Savoye, Claire Garnier-Tixidre, Philippe Toussaint, Agnès Dechartres, Rémy Largillier, Gabriel Baron, Marie-Christine Kaminsky, Dominique Berton, Bruno Valenza, Willy Lescaut, Hortense Laharie-Mineur, Jérôme Alexandre, Anne Floquet, Frédéric Selle, Charles Briac Levache, Hugues Barletta, Philippe Follana, Delphine Mollon-Grange, Catherine Delbaldo, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Institut Bergonié [Bordeaux], Centre Hospitalier Princesse Grace, Centre d'épidémiologie Clinique [Hôtel-Dieu], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Hôtel Dieu, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Centre Léon Bérard [Lyon], Centre Azuréen de Cancérologie [Mougins, France], Institut Jean Godinot [Reims], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Groupe Hospitalier Diaconesses Croix Saint-Simon, Centre Hospitalier Intercommunal de Créteil (CHIC), Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Groupe Hospitalier Mutualiste [Grenoble] (GHM), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Clinique Tivoli Ducos [Bordeaux], Clinique Francheville [Périgueux], Service de gynécologie [Centre hospitalier intercommunal Fréjus Saint-Raphaël], Centre Hospitalier Intercommunal Fréjus - St Raphaël (CHI Fréjus - St Raphaël), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Intercommunal de Cornouaille (CHIC), and Gestionnaire, HAL Sorbonne Université 5
- Subjects
medicine.medical_specialty ,genetic structures ,Bevacizumab ,Identifier NCT01832415 bevacizumab ,Population ,RM1-950 ,bevacizumab ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Progression-free survival ,education ,Prospective cohort study ,Pharmacology ,education.field_of_study ,business.industry ,Brief Research Report ,Carboplatin ,3. Good health ,Clinical trial ,monitoring ,ovarian cancer ,routine clinical practice ,chemistry ,Tolerability ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,030220 oncology & carcinogenesis ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Clinical Trial Registration: ClinicalTrials.gov ,Therapeutics. Pharmacology ,business ,progression-free survival ,medicine.drug - Abstract
Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment administration and outcomes in the French real-world setting.Patients and Methods: Eligible patients were aged ≥ 18 years with planned bevacizumab-containing therapy for newly diagnosed ovarian cancer. The primary objective was to assess the safety profile of front-line bevacizumab in routine clinical practice; secondary objectives were to describe patient characteristics, indications/contraindications for bevacizumab, treatment regimens and co-medications, follow-up and monitoring, progression-free survival, and treatment at recurrence. In this non-interventional study, treatment was administered as chosen by the investigator and participation in the trial had no influence on the management of the disease.Results: Of 1,290 patients screened between April 2013 and February 2015, 468 were eligible. Most patients (86%) received bevacizumab 15 mg/kg every 3 weeks or equivalent, typically with carboplatin (99%) and paclitaxel (98%). The median duration of bevacizumab was 12.2 (range 0–28, interquartile range 6.9–14.9) months; 8% of patients discontinued bevacizumab because of toxicity. The most common adverse events were hypertension (38% of patients), fatigue (35%), and bleeding (32%). There were no treatment-related deaths. Most physicians (90%) reported blood pressure measurement immediately before each bevacizumab infusion and almost all (97%) reported monitoring for proteinuria before each bevacizumab infusion. Median progression-free survival was 17.4 (95% CI, 16.4–19.1) months. The 3-year overall survival rate was 62% (95% CI, 58–67%). The most commonly administered chemotherapies at recurrence were carboplatin and pegylated liposomal doxorubicin.Discussion: Clinical outcomes and tolerability with bevacizumab in this real-life setting are consistent with randomized trial results, notwithstanding differences in the treated patient population and treatment schedule.Clinical Trial Registration:ClinicalTrials.gov, Identifier NCT01832415.
- Published
- 2021
144. Association Between Lack of Blinding and Mortality Results in Critical Care Randomized Controlled Trials: A Meta-Epidemiological Study
- Author
-
Stéphane Gaudry, Agnès Dechartres, Guillaume L. Martin, Florence Tubach, David Hajage, and Théo Trioux
- Subjects
medicine.medical_specialty ,Blinding ,business.industry ,Confounding ,MEDLINE ,Odds ratio ,Critical Care and Intensive Care Medicine ,3. Good health ,law.invention ,Epidemiologic Studies ,Systematic review ,Data extraction ,Randomized controlled trial ,Bias ,Double-Blind Method ,law ,Research Design ,Internal medicine ,Epidemiology ,Medicine ,Humans ,Single-Blind Method ,Hospital Mortality ,business ,Randomized Controlled Trials as Topic - Abstract
OBJECTIVES To investigate whether intervention effect estimates for mortality differ between blinded and nonblinded randomized controlled trials conducted in critical care. We used a meta-epidemiological approach, comparing effect estimates between blinded and nonblinded randomized controlled trials for the same research question. DATA SOURCES Systematic reviews and meta-analyses of randomized controlled trials evaluating a therapeutic intervention on mortality in critical care, published between January 2009 and March 2019 in high impact factor general medical or critical care journals and by Cochrane. DATA EXTRACTION For each randomized controlled trial included in eligible meta-analyses, we evaluated whether the trial was blinded (i.e., double-blinded and/or reporting adequate methods) or not (i.e., open-label, single-blinded, or unclear). We collected risk of bias evaluated by the review authors and extracted trial results. DATA SYNTHESIS Within each meta-analysis, we compared intervention effect estimates between blinded and nonblinded randomized controlled trials by using a ratio of odds ratio (< 1 indicates larger estimates in nonblinded than blinded randomized controlled trials). We then combined ratio of odds ratios across meta-analyses to obtain the average relative difference between nonblinded and blinded trials. Among 467 randomized controlled trials included in 36 meta-analyses, 267 (57%) were considered blinded and 200 (43%) nonblinded. Intervention effect estimates were statistically significantly larger in nonblinded than blinded trials (combined ratio of odds ratio, 0.91; 95% CI, 0.84-0.99). We found no heterogeneity across meta-analyses (p = 0.72; I2 = 0%; τ2 = 0). Sensitivity analyses adjusting the main analysis on risk of bias items yielded consistent results. CONCLUSIONS Intervention effect estimates of mortality were slightly larger in nonblinded than blinded randomized controlled trials conducted in critical care, but confounding cannot be excluded. Blinding of both patients and personnel is important to consider when possible in critical care trials, even when evaluating mortality.
- Published
- 2021
145. Time to resolution of respiratory and systemic coronavirus disease 2019 symptoms in community setting
- Author
-
Aurélien Dinh, Luc Jaulmes, Agnès Dechartres, Clara Duran, Hélène Mascitti, Xavier Lescure, Youri Yordanov, Patrick Jourdain, Apra Caroline (AC), Jaulmes Luc (JL), Mensch Arthur (MA), Aime-Eusebi Amélie, Apra Caroline, Bleibtreu Alexandre, Debuc Erwan, Dechartres Agnes, Deconinck Laurène, Dinh Aurélien, Jourdain Patrick, Katlama Christine, Lebel Josselin, Lescure François-Xavier, Yordanov Youri, Artigou Yves, Banzet Amélie, Boucheron Elodie, Boudier Christiane, Buzenac Edouard, Chapron Marie-Claire, Chekaoui Dalhia, null De Bastard Laurent, Grenier Alexandre, Haas Pierre-Etienne, Hody Julien, Jarraya Michèle, Lacaille Louis, Le Guern Aurélie, Leclert Jeremy, Male Fanny, Marchand-Arvier Jerôme, Martin-Blondet Emmanuel, Nassour Apolinne, Ourahou Oussama, Thomas Penn, Ribardiere Ambre, Robin Nicolas, Rouge Camille, Nicolas Schmidt, and Villie Pascaline
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Symptom duration ,Comorbidity ,Coronary Artery Disease ,Body Mass Index ,Cohort Studies ,Coronary artery disease ,Sequelae ,Pulmonary Disease, Chronic Obstructive ,Risk Factors ,Interquartile range ,Internal medicine ,Diabetes mellitus ,Dyspnoea ,Outpatients ,medicine ,Humans ,Respiratory system ,Asthma ,Coronavirus disease 2019 ,business.industry ,Age Factors ,COVID-19 ,General Medicine ,Middle Aged ,medicine.disease ,Telemedicine ,Research Note ,Infectious Diseases ,Heart failure ,Community setting ,Female ,Median body ,business ,Cohort study - Abstract
Objectives To assess the time to resolution of respiratory and systemic symptoms and their associated factors in outpatients during the coronavirus disease 2019 (COVID-19) pandemic. Methods Cohort study including adult outpatients, managed with Covidom, a telesurveillance solution, with RT-PCR-confirmed diagnosis, from 9 March 2020 until 23 February 2021. Follow up was 30 days after symptom onset. Results Among the 9667 patients included, mean age was 43.2 ± 14.0 years, and 67.5% were female (n = 6522). Median body mass index (BMI) was 25.0 kg/m2 (interquartile range 22.1–28.8 kg/m2). Main co-morbidities were: hypertension (12.9%; n = 1247), asthma (11.0%; n = 1063) and diabetes mellitus (5.5%; n = 527). The most frequent symptom during follow up was dyspnoea (65.1%; n = 6296), followed by tachypnoea (49.9%; n = 4821), shivers (45.6%; n = 4410) and fever (36.7%; n = 3550). Median times to resolution of systemic and respiratory symptoms were 3 days (95% CI 2−4 days) and 7 days (95% CI 6−8 days), respectively. Ultimately, 17.2% (95% CI 15.7%−18.8%) still presented respiratory symptoms at day 30. Longer time to respiratory symptom resolution was associated with older age, increased BMI, chronic obstructive pulmonary disease, coronary artery disease, asthma and heart failure. Regarding systemic symptoms, coronary artery disease, asthma, age above 40 years and elevated BMI were associated with longer time to resolution. Conclusions Time to symptom resolution among outpatients with COVID-19 seemed shorter for systemic than respiratory symptoms. Prolonged respiratory symptoms were common at day 30. Risk factors associated with later resolution included age, and cardiovascular and pulmonary diseases.
- Published
- 2021
146. Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
- Author
-
Berton, Dominique, primary, Floquet, Anne, additional, Lescaut, Willy, additional, Baron, Gabriel, additional, Kaminsky, Marie-Christine, additional, Toussaint, Philippe, additional, Largillier, Rémy, additional, Savoye, Aude-Marie, additional, Alexandre, Jérôme, additional, Delbaldo, Catherine, additional, Malaurie, Emmanuelle, additional, Barletta, Hugues, additional, Bosacki, Claire, additional, Garnier-Tixidre, Claire, additional, Follana, Philippe, additional, Laharie-Mineur, Hortense, additional, Briac Levache, Charles, additional, Valenza, Bruno, additional, Dechartres, Agnès, additional, Mollon-Grange, Delphine, additional, and Selle, Frédéric, additional
- Published
- 2021
- Full Text
- View/download PDF
147. Comment on “Maternal use of fluconazole and congenital malformations in the progeny: A meta-analysis of the literature”
- Author
-
Marin, B., primary, Vauzelle, C., additional, Coulm, B., additional, Beghin, D., additional, Latour, M., additional, Tubach, F., additional, Dechartres, A., additional, and Elefant, E., additional
- Published
- 2021
- Full Text
- View/download PDF
148. Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials
- Author
-
Salem, Joe-Elie, primary, Ederhy, Stephane, additional, and Dechartres, Agnès, additional
- Published
- 2021
- Full Text
- View/download PDF
149. Effectiveness of simulation in psychiatry for nursing students, nurses and nurse practitioners: A systematic review and meta‐analysis
- Author
-
Piot, Marie‐Aude, primary, Dechartres, Agnès, additional, Attoe, Chris, additional, Romeo, Marie, additional, Jollant, Fabrice, additional, Billon, Grégoire, additional, Cross, Sean, additional, Lemogne, Cédric, additional, Layat Burn, Carine, additional, Michelet, Daphné, additional, Guerrier, Gilles, additional, Tesniere, Antoine, additional, Rethans, Jan‐Joost, additional, and Falissard, Bruno, additional
- Published
- 2021
- Full Text
- View/download PDF
150. Les engelures : un facteur pronostique associé à moins d’hospitalisations pour COVID-19
- Author
-
Mascitti, H., primary, Jourdain, P., additional, Bleibtreu, A., additional, Jaulmes, L., additional, Dechartres, A., additional, Lescure, X., additional, Yordanov, Y., additional, and Dinh, A., additional
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.